Abstract BACKGROUND: Osteonecrosis of the jaw is a well known potential complication of bisphosphonate treatment but its pathogenesis is poorly understood. The current management of patients with bisphosphonate-associated osteonecrosis (BON) is based on "expert recommendations" and there is a recognized need of better evidence. We report two cases where BON hid jaw metastases and use them to discuss some limitations of the current recommendations. PATIENTS: Two patients undergoing long-term I.V. amino-bisphosphonate treatment for metastatic cancer presented with areas of intraorally exposed jawbone. Bisphosphonate-associated osteonecrosis was diagnosed on the basis of medical history, clinical and radiological features. They underwent sur...
To understand the clinical features of osteonecrosis of the jaw after bisphosphonates use for therap...
Bisphosphonate-related osteonecrosis of the jaws (BON), first described in 2003, is gaining importan...
Clinicians use bisphosphonates in neoplastic and metabolic bone diseases. Osteonecrosis is the main ...
Background: Osteonecrosis of the jaw is a well known potential complication of bisphosphonate treatm...
OBJECTIVE: Bisphosphonates are chemically stable analogs of pyrophosphate compounds, which have been...
Osteonecrosis of the jaw (ONJ) is a well known complication in patients treated with bisphosphonates...
BISPHOSPHONATE RELATEDOSTEONECROSIS OF THE JAW AND ITS MANAGEMENTObjective: Bisphosphonatesare commo...
Objective. Bone metastases are a major cause of morbidity in cancer patients. Treatment includes bis...
Bisphosphonates are widely used in the management of metastatic disease to bone and in diseases of a...
Bisphosphonates are used for the standard of care of patients with skeletal metastases and hypocalce...
Introduction: Bisphosphonates are efficiently used to treat osteoporosis, bone metastases of maligna...
Purpose Bisphosphonates (BPs) are bone-remodeling inhibitors that are used to manage bone metastases...
BACKGROUND: In recent years, several cases of mandibular necrosis associated with long-term use ...
PURPOSE: The risk of osteonecrosis of the jaw (ONJ) associated with bisphosphonate use in patients w...
The incidence of bone metastases is high among patients with advanced cancer. Bone metastases occur ...
To understand the clinical features of osteonecrosis of the jaw after bisphosphonates use for therap...
Bisphosphonate-related osteonecrosis of the jaws (BON), first described in 2003, is gaining importan...
Clinicians use bisphosphonates in neoplastic and metabolic bone diseases. Osteonecrosis is the main ...
Background: Osteonecrosis of the jaw is a well known potential complication of bisphosphonate treatm...
OBJECTIVE: Bisphosphonates are chemically stable analogs of pyrophosphate compounds, which have been...
Osteonecrosis of the jaw (ONJ) is a well known complication in patients treated with bisphosphonates...
BISPHOSPHONATE RELATEDOSTEONECROSIS OF THE JAW AND ITS MANAGEMENTObjective: Bisphosphonatesare commo...
Objective. Bone metastases are a major cause of morbidity in cancer patients. Treatment includes bis...
Bisphosphonates are widely used in the management of metastatic disease to bone and in diseases of a...
Bisphosphonates are used for the standard of care of patients with skeletal metastases and hypocalce...
Introduction: Bisphosphonates are efficiently used to treat osteoporosis, bone metastases of maligna...
Purpose Bisphosphonates (BPs) are bone-remodeling inhibitors that are used to manage bone metastases...
BACKGROUND: In recent years, several cases of mandibular necrosis associated with long-term use ...
PURPOSE: The risk of osteonecrosis of the jaw (ONJ) associated with bisphosphonate use in patients w...
The incidence of bone metastases is high among patients with advanced cancer. Bone metastases occur ...
To understand the clinical features of osteonecrosis of the jaw after bisphosphonates use for therap...
Bisphosphonate-related osteonecrosis of the jaws (BON), first described in 2003, is gaining importan...
Clinicians use bisphosphonates in neoplastic and metabolic bone diseases. Osteonecrosis is the main ...